---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-165406"
form_type: "8-K"
ticker: "COYA"
cik: "0001835022"
company_name: "Coya Therapeutics, Inc."
filed_at: "2023-06-12T23:59:59+00:00"
generated_at: "2026-06-14T03:12:24.832143+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Coya CEO update: ALS POC shows disease halted 24wks; AD Phase2 data due Q2 2024

## Summary
- COYA 302 in ALS: disease progression halted to week 24 with minimal decline to week 48 on ALSFRS scale in open-label study.
- COYA 301 in AD: cognitive function improved or stabilized; Treg function enhanced, cytokines reduced, neuroinflammation decreased.
- Pre-IND meeting with FDA for COYA 302 planned fall 2023; IND submission early 2024 with Phase 2 trial to follow.
- Academic double-blind Phase 2 trial of low-dose IL-2 in AD (funded by Gates Foundation) top-line data expected Q2 2024.
- Appointed immunologist Dr. Guillaume Dorothee to SAB; hired Arun Swaminathan as business development executive.

## SEC filing metadata
- accession: 0001193125-23-165406
- form_type: 8-K
- ticker: COYA
- cik: 0001835022
- company_name: Coya Therapeutics, Inc.
- filed_at: 2023-06-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1835022/000119312523165406/0001193125-23-165406-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1835022/000119312523165406/d514893d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-165406
- JSON: https://secwatch.observer/filing/0001193125-23-165406.json
- Plain text: https://secwatch.observer/filing/0001193125-23-165406.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.